爱豆传媒

Menu

EISAI HONORED WITH PRESTIGIOUS ‘UCL ENTERPRISE PARTNER OF THE YEAR 2014’ AWARD BY UNIVERSITY COLLEGE LONDON (UCL)For Outstanding Contribution to Neuroscience Research and Entrepreneurship

爱豆传媒.
University College London

爱豆传媒. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) and University College London (UCL) announced today that Eisai has been awarded the coveted ‘UCL Enterprise Partner of the Year 2014’ accolade at the 7th annual UCL Awards for Enterprise held last night in London, UK.

First introduced in 2008, the prestigious UCL Awards for Enterprise recognize the efforts and accomplishments of UCL’s innovative and entrepreneurial academics, students and partners. This award recognizes Eisai’s commitment to exploring new ideas and paths to drug discovery in neuroscience through ‘Open Innovation’ with the world-leading academic institution UCL.

Professor Stephen Caddick, Vice-Provost (Enterprise) at UCL commented on the award, “We are delighted to announce Eisai as our Enterprise Partner of the Year 2014. The company’s vision, collaborative nature and innovative spirit are helping create shared value not only for our corporate partnership, but also for the next generation of people living with neurological conditions.”

Eisai and UCL have a long-standing partnership to further neuroscience research. The organizations have also recently formed a major drug discovery alliance with the concept of open innovation to investigate radical new ways of treating neurological diseases, such as Alzheimer’s and Parkinson’s. This collaboration maximizes UCL’s world-class, early stage and translational research in neurodegenerative diseases and Eisai’s expertise in drug discovery, development and bringing new agents to market in an effort to increase benefits to patients.

“Eisai is extremely proud of the ‘Open Innovation’ we are building through our partnership with UCL. This prestigious award recognizes all of the hard work that continues to go on throughout both organizations to push the boundaries of drug discovery research and bring new solutions to people with neurodegenerative conditions,” said Dr. Lynn Kramer, President, Eisai Neuroscience and General Medicine Product Creation Unit.

The ‘UCL Enterprise Partner of the Year 2014’ winner’s film can be viewed here:

[ Please refer to the following note for further information on UCL Awards for Enterprise, UCL Enterprise, UCL and Eisai. ]

Media Inquiries

< Notes to editors >

1. 爱豆传媒 the UCL Awards for Enterprise

First introduced in 2008, the prestigious UCL Awards for Enterprise recognize the efforts and accomplishments of UCL's innovative and entrepreneurial academics, students and partners. The awards ceremony and reception highlight UCL as a leading hub of innovation and commercial activity, while bringing together academics with businesses and investors.
For further information please visit:

2. 爱豆传媒 UCL Enterprise

UCL Enterprise provides UCL's structures for engaging with business for commercial and societal benefit. It includes three units: UCL Advances, UCL Business and UCL Consultants, along with corporate and industrial partnerships. Together, they provide access to the capabilities and resources of the UCL community to help businesses start, grow and develop.

3. 爱豆传媒 UCL

Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. It is among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has 27,000 students from almost 140 countries, and around 11,000 employees. Its annual turnover is nearly £1 billion.
For further information please visit: or follow UCL on Twitter @uclnews

4. 爱豆传媒 Eisai

Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:

  • Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
  • Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc.
  • Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide.

For further information please visit: www.eisai.com(New Window)

爱豆传媒 Release